The Insider Selling: Intercept Pharmaceuticals, Inc. (ICPT) Insider Sells 142 Shares of Stock

The Insider Selling: Intercept Pharmaceuticals, Inc. (ICPT) Insider Sells 142 Shares of Stock

Lisa Bright also recently made the following trade(s):

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) insider Lisa Bright sold 142 shares of Intercept Pharmaceuticals stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $110.29, for a total transaction of $15,661.18. Following the transaction, the insider now directly owns 23,477 shares of the company’s stock, valued at $2,589,278.33. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Intercept Pharmaceuticals, Inc. (NASDAQ ICPT) traded down 5.20% during midday trading on Wednesday, reaching $105.00. 1,049,264 shares of the company traded hands. The firm’s market capitalization is $2.63 billion. Intercept Pharmaceuticals, Inc. has a one year low of $96.63 and a one year high of $177.93. The firm has a 50-day moving average price of $124.94 and a 200-day moving average price of $118.29.

Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) EPS for the quarter, topping the consensus estimate of ($3.62) by $0.16. Intercept Pharmaceuticals had a negative return on equity of 119.17% and a negative net margin of 543.35%. The business had revenue of $30.89 million during the quarter, compared to the consensus estimate of $27.50 million. During the same quarter last year, the company earned ($3.14) EPS. The firm’s revenue was up 459.6% compared to the same quarter last year. Equities analysts predict that Intercept Pharmaceuticals, Inc. will post ($14.40) EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Intercept Pharmaceuticals by 4.7% in the first quarter. Vanguard Group Inc. now owns 1,270,984 shares of the biopharmaceutical company’s stock valued at $143,749,000 after buying an additional 56,952 shares in the last quarter. State Street Corp increased its position in shares of Intercept Pharmaceuticals by 7.3% in the first quarter. State Street Corp now owns 805,550 shares of the biopharmaceutical company’s stock valued at $91,110,000 after buying an additional 54,523 shares in the last quarter. First Trust Advisors LP increased its position in shares of Intercept Pharmaceuticals by 17.0% in the second quarter. First Trust Advisors LP now owns 287,411 shares of the biopharmaceutical company’s stock valued at $34,797,000 after buying an additional 41,856 shares in the last quarter. Macquarie Group Ltd. increased its position in shares of Intercept Pharmaceuticals by 54.2% in the first quarter. Macquarie Group Ltd. now owns 241,565 shares of the biopharmaceutical company’s stock valued at $27,321,000 after buying an additional 84,954 shares in the last quarter. Finally, Point72 Asset Management L.P. increased its position in shares of Intercept Pharmaceuticals by 13.1% in the first quarter. Point72 Asset Management L.P. now owns 220,600 shares of the biopharmaceutical company’s stock valued at $24,950,000 after buying an additional 25,500 shares in the last quarter. Institutional investors and hedge funds own 84.27% of the company’s stock.

A number of equities analysts have commented on ICPT shares. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating on shares of Intercept Pharmaceuticals in a research report on Wednesday, April 12th. Credit Suisse Group lifted their price objective on shares of Intercept Pharmaceuticals from $198.00 to $201.00 and gave the stock an “outperform” rating in a research report on Friday, May 5th. Jefferies Group LLC started coverage on shares of Intercept Pharmaceuticals in a research report on Monday, July 10th. They set a “buy” rating and a $275.00 price objective for the company. Laidlaw raised shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating and set a $115.00 price objective for the company in a research report on Friday, May 5th. Finally, Zacks Investment Research cut shares of Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, May 1st. Three investment analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Intercept Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $196.39.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Related posts

Leave a Comment